Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott Laboratories Announces 10-Year Data Evaluating HUMIRA (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis


Wednesday, 6 Jun 2012 01:10am EDT 

Abbott Laboratories announced results from two long-term, open-label studies, which evaluated the results of HUMIRA (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). These 10-year HUMIRA studies, DE019 and DE020, are among the longest, open-label trials in RA. Results presented, include information on clinical response, radiographic inhibition and physical function data in patients with long-standing RA. In both studies, patients were assessed for improvements in signs and symptoms of the disease, such as joint pain, swelling and stiffness, as well as physical function and achievement of clinical remission. Following up to 10 years of HUMIRA therapy, patients in the studies continued to maintain improvements in disease activity. In both DE019 and DE020, a DAS28 (CRP) <2.6, a measure of clinical remission, was observed in more than half of patients who continued on HUMIRA for up to 10 years (59.6% and 57.2%, respectively). A DAS28 score of <2.6 as a measure of clinical remission is supported by both EULAR and the American College of Rheumatology (ACR). DE019 also assessed the ability of HUMIRA to inhibit radiographic progression. Patients who completed 10 years of treatment and also had X-rays available at baseline and year 10 demonstrated an average change of 2.8 in modified total Sharp score (mTSS), a measure of radiographic inhibition. 

Company Quote

38.93
0.55 +1.43%
17 Apr 2014